Scholarlink

<p>Our knowledge of the pathogenesis, tumor biology, and clinical course of ovarian cancer has improved significantly during the past two decades. At the same time, the introduction of new therapeutic principles—anti-angiogenesis and poly(ADP-ribose) polymerase (PARP) inhibition—has extended the therapeutic options and led to establishment of maintenance therapy in about 80% of primary cases. By applying approved selection criteria, an notable improvement in progression-free and overall survival can be achieved in both primary and relapsed settings. Longer treatment with complex drugs causes long-term sequelae in &gt; 50% of cases, including mental and functional impairment. Strict limitation of the duration of surveillance after ovarian cancer treatment is therefore not appropriate. In general, there is a&#xa0;great need for innovative, risk-stratified surveillance concepts, in which the patient’s subjective wellbeing is the central aspect and which is continuously monitored using patient-reported outcome measures (PROMs).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nachsorge Ovarialkarzinom: zwischen Erhaltungstherapie und Rezidiv

  • 期刊论文

  • 发表日期：

    2026年1月29日

查看全文
  • Willibald Schröder

摘要

Our knowledge of the pathogenesis, tumor biology, and clinical course of ovarian cancer has improved significantly during the past two decades. At the same time, the introduction of new therapeutic principles—anti-angiogenesis and poly(ADP-ribose) polymerase (PARP) inhibition—has extended the therapeutic options and led to establishment of maintenance therapy in about 80% of primary cases. By applying approved selection criteria, an notable improvement in progression-free and overall survival can be achieved in both primary and relapsed settings. Longer treatment with complex drugs causes long-term sequelae in > 50% of cases, including mental and functional impairment. Strict limitation of the duration of surveillance after ovarian cancer treatment is therefore not appropriate. In general, there is a great need for innovative, risk-stratified surveillance concepts, in which the patient’s subjective wellbeing is the central aspect and which is continuously monitored using patient-reported outcome measures (PROMs).